For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

This Siklos Patient Guide contains important information about your treatment, or your child's treatment including advice on preparation and administration of your medicine, disease symptoms, and side effects.

This Physician Guide for Siklos contains important recommendations for patient monitoring, dosage adjustments, and the management of serious adverse effects.

Dosing sheet for physicians to illustrate and record patient's individual daily dosage requirements.

This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Simponi

Important risk minimisation information for Patients:

How to take Sodium oxybate 500 mg/ml oral solution Brochure

Important risk minimisation information for Patients and Caregivers:

Sodium oxybate 500 mg/ml oral solution

Frequently Asked Questions (FAQ)

Safety information card for patients, physicians and pharmacists

Important risk minimisation information for Healthcare Professionals:

Sodium oxybate 500 mg/ml oral solution Treatment Initiation and Follow-Up Visit Form

GUIDE FOR PAEDIATRIC PATIENTS AND THEIR CAREGIVERS

IMPORTANT INFORMATION ABOUT SAFE USE AND HANDLING OF SODIUM OXYBATE

Sodium Oxybate 500 mg/ml Oral Solution

Frequently Asked Questions Information Sheet

Important risk minimisation information for Patients.

How to take Sodium oxybate 500 mg/ml oral solution Brochure.

Sodium Oxybate 500 mg/ml oral solution

Patient card

Sodium Oxybate 500 mg/ml oral solution

Important risk minimisation information for Healthcare Professionals: Treatment Initiation and Follow-Up Visit Form

In this guide the patient is warned about the risks (of respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis) and is told how to proceed in the event of experiencing them.

Guidance for paediatric patients and their caregivers - Important information about safe use and handling of Sodium Oxybate 500 mg/ml oral solution (sodium oxybate).

IMPORTANT RISK MINIMISATION INFORMATION FOR PATIENTS:

How to take SODIUM OXYBATE 500mg/ml Oral solution

This treatment initiation form should be completed by Healthcare Professionals as it is essential to ensure the safe and effective use of Sodium Oxybate 500 mg/ml oral solution and the appropriate management of the important risks. All sections of this form need to be completed, signed and dated and retained in the patient's medical records.

This guide contains recommendations to minimise the risks of respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis.

This guide contains recommendations to avoid the risks (respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis) and patients are advised to carry this with them at all times.

Healthcare Professional (HCP) educational material on important safety information associated with Valproate use.

Patient Guide on important safety information associated with Valproate use - educational material

FOR DISPENSARY USE ONLY Pharmacy poster with key information about the Pregnancy Prevention Programme.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Educational material for patients on important safety information associated with valproate use.

Educational material for patients on important safety information associated with valproate use.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

As part of the UK RMMs for Spravato, the Chief Pharmacist must acknowledge the need to maintain detail on the Spravato Patient Register & Alert System.

This guide informs healthcare professionals about the four identified risks that may occur following Spravato treatment: transient dissociative states and perception disorders (dissociation), disturbances in consciousness (sedation), increased blood pressure and drug abuse. This guide describes the risks and explains how to minimise and manage them.

If you are being treated with Spravato, it is important that you understand the possible risks of taking this medicine. This guide will explain these risks and give you information about how you and your healthcare professional can reduce these risks. This guide does not replace the patient information leaflet that comes with your medicine and you should ensure you have read this prior to taking Spravato.

The treating healthcare professional should use their clinical judgement and this checklist to decide whether the patient is ready to leave after Spravato administration.

PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Checklist for prescribers

PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient card

PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient sheet

This is for healthcare professionals to provide to male patients taking valproate as well as their families and caregivers.

Valproate (Blevo, Convulex, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): review by two specialists is required for initiating valproate but not for male patients already taking valproate.

Risk minimisation measures required for Valproate prescribing - This is for the patient 55 years old or over

Risk minimisation measures required for Valproate prescribing - This is for the female patients less than 55 years old.

Risk minimisation measures required for Valproate prescribing - This is for the male patients less than 55 years old.

This information does not replace the overall discussion on risks and benefits which would lead to an informed prescribing decision.